CN102272295A - 活减毒呼吸道合胞病毒 - Google Patents

活减毒呼吸道合胞病毒 Download PDF

Info

Publication number
CN102272295A
CN102272295A CN2009801537266A CN200980153726A CN102272295A CN 102272295 A CN102272295 A CN 102272295A CN 2009801537266 A CN2009801537266 A CN 2009801537266A CN 200980153726 A CN200980153726 A CN 200980153726A CN 102272295 A CN102272295 A CN 102272295A
Authority
CN
China
Prior art keywords
leu
ile
lys
asn
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801537266A
Other languages
English (en)
Chinese (zh)
Inventor
M.K.亚戈迪奇
M.P.奇特伦
D.J.迪斯特法诺
D.L.克拉
梁小平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN102272295A publication Critical patent/CN102272295A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18564—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN2009801537266A 2008-11-05 2009-11-03 活减毒呼吸道合胞病毒 Pending CN102272295A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19832708P 2008-11-05 2008-11-05
US61/198327 2008-11-05
PCT/US2009/063024 WO2010053883A1 (en) 2008-11-05 2009-11-03 Live, attentuated respiratory syncytial virus

Publications (1)

Publication Number Publication Date
CN102272295A true CN102272295A (zh) 2011-12-07

Family

ID=41527812

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801537266A Pending CN102272295A (zh) 2008-11-05 2009-11-03 活减毒呼吸道合胞病毒

Country Status (19)

Country Link
US (1) US9011876B2 (https=)
EP (1) EP2346990B1 (https=)
JP (2) JP5016731B2 (https=)
KR (1) KR20110063863A (https=)
CN (1) CN102272295A (https=)
AU (1) AU2009311287C1 (https=)
BR (1) BRPI0921424A2 (https=)
CA (1) CA2742086A1 (https=)
CL (1) CL2011000999A1 (https=)
CO (1) CO6362047A2 (https=)
EC (1) ECSP11011033A (https=)
IL (1) IL212437A0 (https=)
MA (1) MA32878B1 (https=)
MX (1) MX2011004719A (https=)
PE (1) PE20110394A1 (https=)
RU (1) RU2011122615A (https=)
TN (1) TN2011000182A1 (https=)
WO (1) WO2010053883A1 (https=)
ZA (1) ZA201103259B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105189756A (zh) * 2013-03-14 2015-12-23 爱默蕾大学 具有沉默突变的重组rsv、疫苗及其相关方法
CN111344008A (zh) * 2017-09-15 2020-06-26 俄亥俄州创新基金会 用于预防呼吸道合胞病毒(rsv)感染的疫苗及其制备和使用方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2742086A1 (en) * 2008-11-05 2010-05-14 Merck Sharp & Dohme Corp. Live, attenuated respiratory syncytial virus
EP2744894A4 (en) * 2011-08-18 2015-04-22 Ycine Llc PRODUCTION OF INFECTIOUS RNA VIRUSES IN YEAST
WO2013031827A1 (ja) 2011-08-29 2013-03-07 国立大学法人徳島大学 Rsv粘膜ワクチン
US9957486B2 (en) 2013-02-08 2018-05-01 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization
CA2926696A1 (en) 2013-10-16 2015-04-23 Merck Sharp & Dohme Corp Thermostable respiratory synctial virus (rsv) vaccine compositions
WO2015057540A1 (en) 2013-10-16 2015-04-23 Merck Sharp & Dohme Corp. Method of microwave vacuum drying spherical-shaped pellets of biological materials
US10947512B2 (en) * 2015-08-14 2021-03-16 Research Institute At Nationwide Children's Hospital Respiratory syncytial virus having altered NS1 protein function and related materials and methods
MX2018005462A (es) 2015-10-29 2018-08-01 Univ Emory Composiciones inmunogénicas de rsv quimérico y métodos de uso.
EP3515930A1 (en) 2016-09-23 2019-07-31 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
TW202535439A (zh) * 2023-11-17 2025-09-16 美商賽諾菲巴斯德公司 海藻糖疫苗調配物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0917592A4 (en) * 1996-04-04 2002-04-24 Univ Michigan REDUCED RSV
JP2002507408A (ja) 1998-03-26 2002-03-12 アメリカン・サイアナミド・カンパニー 麻疹ウイルスもしくはヒト呼吸合胞体ウイルスサブグループｂの弱毒化の原因である突然変異
CN100354425C (zh) 1999-07-09 2007-12-12 美国政府健康及人类服务部 减毒的人－牛嵌合呼吸道合胞病毒疫苗的生产
AU2003295339B2 (en) 2002-09-27 2009-03-26 Medimmune, Llc Functional mutations in respiratory syncytial virus
CA2520671C (en) * 2003-03-28 2014-03-18 Medimmune Vaccines, Inc. Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
JPWO2008096811A1 (ja) * 2007-02-07 2010-05-27 ディナベック株式会社 弱毒化マイナス鎖ｒｎａウイルス
CA2742086A1 (en) * 2008-11-05 2010-05-14 Merck Sharp & Dohme Corp. Live, attenuated respiratory syncytial virus

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105189756A (zh) * 2013-03-14 2015-12-23 爱默蕾大学 具有沉默突变的重组rsv、疫苗及其相关方法
CN105189756B (zh) * 2013-03-14 2021-06-11 爱默蕾大学 具有沉默突变的重组rsv、其相关疫苗和方法
CN113322264A (zh) * 2013-03-14 2021-08-31 爱默蕾大学 具有沉默突变的重组rsv、其相关疫苗和方法
CN113322264B (zh) * 2013-03-14 2024-05-31 爱默蕾大学 具有沉默突变的重组rsv、其相关疫苗和方法
CN111344008A (zh) * 2017-09-15 2020-06-26 俄亥俄州创新基金会 用于预防呼吸道合胞病毒(rsv)感染的疫苗及其制备和使用方法

Also Published As

Publication number Publication date
AU2009311287C1 (en) 2015-02-19
EP2346990A1 (en) 2011-07-27
ZA201103259B (en) 2012-01-25
US9011876B2 (en) 2015-04-21
CA2742086A1 (en) 2010-05-14
EP2346990B1 (en) 2016-01-06
IL212437A0 (en) 2011-06-30
ECSP11011033A (es) 2011-12-30
WO2010053883A1 (en) 2010-05-14
JP2012507302A (ja) 2012-03-29
CL2011000999A1 (es) 2012-07-20
RU2011122615A (ru) 2012-12-20
BRPI0921424A2 (pt) 2016-01-05
JP5743794B2 (ja) 2015-07-01
JP5016731B2 (ja) 2012-09-05
TN2011000182A1 (en) 2012-12-17
AU2009311287B2 (en) 2013-02-07
AU2009311287A1 (en) 2010-05-14
KR20110063863A (ko) 2011-06-14
MX2011004719A (es) 2011-05-31
PE20110394A1 (es) 2011-06-22
JP2011250798A (ja) 2011-12-15
CO6362047A2 (es) 2012-01-20
MA32878B1 (fr) 2011-12-01
US20110212130A1 (en) 2011-09-01

Similar Documents

Publication Publication Date Title
CN102272295A (zh) 活减毒呼吸道合胞病毒
CN111560354B (zh) 重组新型冠状病毒及其制备方法和应用
AU2021218112B2 (en) Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes
TW200930816A (en) Metapneumovirus strains as vaccine formulations and as vectors for expression of heterologous antigenic sequences
JP2012507302A5 (https=)
CN113322264B (zh) 具有沉默突变的重组rsv、其相关疫苗和方法
CN109266622A (zh) 重组改良型安卡拉痘苗病毒(mva)呼吸道合胞病毒(rsv)疫苗
JP2011250798A5 (https=)
US10329584B2 (en) Modified Sendai virus vaccine and imaging vector
AU2016366771B2 (en) Recombinant respiratory syncytial virus strains with mutations in the M2-2 ORF providing a range of attenuation phenotypes
JP7063808B6 (ja) Ｎｓ１およびｎｓ２遺伝子シフトを含む組換えｒｓウイルス株
CN110996998A (zh) 表达rsv g的重组嵌合牛/人副流感病毒3及其用途
KR20230038205A (ko) 키메라 rsv 및 코로나바이러스 단백질, 면역원성 조성물, 및 사용 방법
KR20230021115A (ko) 생 약독화된 호흡기 세포융합 바이러스 (live attenuated respiratory syncytial virus)
CN113490507A (zh) 在禽细胞系上生产病毒疫苗
Liu et al. Evaluation of a virus derived from MDCK cells infected persistently with influenza A virus as a potential live‐attenuated vaccine candidate in the mouse model
HK1260544A1 (en) Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: SCHERING CORP (US)

Free format text: FORMER OWNER: MSD CORP.

Effective date: 20121101

C41 Transfer of patent application or patent right or utility model
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: New jersey, USA

Applicant after: MERCK SHARP & DOHME Corp.

Address before: New jersey, USA

Applicant before: SCHERING Corp.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: SCHERING CORP (US) TO: MSD CORP.

TA01 Transfer of patent application right

Effective date of registration: 20121101

Address after: New jersey, USA

Applicant after: SCHERING Corp.

Address before: New jersey, USA

Applicant before: MERCK SHARP & DOHME Corp.

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20111207